5Meier B, Palacios I, Windecker $, et al. Transcatheter left atrial appendage occlusion with Amplatzer devices to obvfate anticoagulation in patfents with atriaf ffbrillatfon[J].Oatheter Cardiovasc Interv, 2005,60(5):417-422.
2Waldo AL. Management of atrial fibrillation : the need for AFFIRMative action.AFFIRM investigators. Atrial Fibrillation Follow-up Investigation of Rhythm Management [ J ]. Am J Cardiol, 1999,84 ( 6 ) :698 -700.
3Wyse DG, Wahto AL, DiMareo JP, et al. Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators [ J ]. N Engl J Med,2002, 347(23) :1825-1833.
4van Gelder IC, Hagens VE, Bosker HA,et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation[ J]. N Engl J Med, 2002,347 ( 23 ) : 1834 -1840.
5Cleland JG, Coletta AP, Abdellah AT, et al. Clinical trials update from the American Heart Association 2007 : CORONA, RethinQ, MASCOT, AF-CHF, HART, MASTER,POISE and stem cell therapy [ J ]. Eur J Heart Fail, 2008,10 ( 1 ) : 102-108.
6Singh BN, Vaughan Williams EM. The effect of amiodarone, a new anti-anginal drug, on cardiac muscle [ J ]. Br J Pharmacol, 1970,39 ( 4 ) :657-667.
7Vorperian VR, Havighurst TC, Miller S, et al. Adverse effects of low dose amiodarone : a meta-analysis [ J ]. J Am Coll Cardiol, 1997,30 ( 3 ) : 791-798.
8Sun W,Sarma JS,Singh BN. Electrophysiological effects of dronedarone ( SR33589), a noniodinated benzofuran derivative, in the rabbit heart : comparison with amiodarone [ J ]. Circulation, 1999,100 ( 22 ) : 2276 -2281.
9Singh BN, Connotly SJ, Crijns HJ, et al. EURIDIS and ADONIS Investigators Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter[ J ]. N Engl J Med,2007,357(10) :987-999.
10Kober L. Antiarrhythmic Trial With Dronedarone in Moderate to Severe CHF Evaluating Morbidity Decrease (ANDROMEDA), NCT00543699. Terminated Jan 2003. Available at : http ://clinicahrials. Gov/ct2/show/record/NCTO0543699. Accessed December 14,2007.
9Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: An analysis of the RE-LY trial[J]. The Lancet, 2010, 376(9745):975-983.
10Wann L S, Curtis AB, Ellenbogen K A, et al. 2011 AC- CF/AHA/HRS focused update on the management of pa- tients with atrial fibrillation (update on Dabigatran): A Report of the American College of Cardiology Foundation Foundation/American Heart Association Task Force on Practice Guidelines[J]. Journal of the American College ofCardiology, 2011,57( 11 ) : 1330-1337.
